Policy approach to optimize multiple myeloma treatment sequencing practices
Uncertainty plays a central role in shaping sequencing practices in MM, underscoring the need for better evidence to guide decisions and avoid suboptimal use of treatment options. As the therapeutic landscape continues to expand, sequencing will be even more complex, which necessitates international coordinated efforts. The multi-stakeholder discussion presented here represents an initial step toward enabling such joint actions.
Authors
- Solène Clavreul (ORCID: https://orcid.org/0000-0001-5384-8425)
- Tamás Ágh (ORCID: https://orcid.org/0000-0002-9609-0236)
- Cristina Entrala Cerezo
- Francesca Maria Gay
- Blanca Gros Otero
- Maria Theresa Krauth
- J Espin
- Zsuzsa Réka Pozsár
- Lise-Lott Eriksson
- Zoltán Kaló
- Monica Racovita
- Johan Severence
Institutions
- Semmelweis University (HU)
- Janssen (France) (FR)
- The Patients Association (GB)
- Syreon Research Institute (Hungary) (HU)
- University of Turin (IT)
- Tata Consultancy Services (India) (IN)
- Andalusian School of Public Health (ES)
- Medical University of Vienna (AT)
- University of Pecs (HU)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1080/17474086.2026.2634278
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00